Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10258791 | 0.93 | TAS1R3 (0.52) | LMNATAS1R3TAS1R1TAS1R2PDE2A | |
| SCHEMBL10252477 | 0.88 | DHODH (0.54) | LMNATAS1R3TAS1R1TAS1R2PDE2A | |
| SCHEMBL10252923 | 0.88 | HDAC8 (0.57) | LMNATAS1R3TAS1R1TAS1R2PDE2A | |
| SCHEMBL10247155 | 0.84 | LMNA (0.77) | LMNATAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL10246997 | 0.84 | LMNA (0.62) | LMNATAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL10246865 | 0.82 | LMNA (0.54) | LMNATAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL22500096 | 0.81 | LMNA (0.56) | LMNATAS1R3TAS1R1TAS1R2PDE2A | |
| SCHEMBL10254152 | 0.79 | DHODH (0.56) | TAS1R3TAS1R1TAS1R2PDE2ADHODH | |
| SCHEMBL10247153 | 0.77 | LMNA (0.50) | LMNATAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL10256809 | 0.77 | CNR1 (0.54) | LMNATAS1R3TAS1R1TAS1R2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | LMNA 1529/4885TAS1R3 3594/4885TAS1R1 3179/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | LMNA 2546/4885TAS1R3 3997/4885TAS1R1 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.